BDBM391338 Trans 2-(4-(3-Fluoroazetidin- 1-yl)-1-(3-((2-methyl-1,1- dioxido-2,3-dihydro- benzo[d]isothiazol-6- yl)amino)-4-oxo-4,5-dihydro- 1H-pyrazolo[4,3-c]pyridin-1- yl)cyclohexyl)acetonitrile::US9957264, Example 18-32

SMILES: CN1Cc2cc(Nc3nn(c4cc[nH]c(=O)c34)[C@@]3(CC#N)CC[C@@H](CC3)N3CC(F)C3)ccc2S1(=O)=O

InChI Key:

Data: 2 IC50

Find this compound or compounds like it in BindingDB or PDB:

Substructure Similarity at least:  must be >=0.5 Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 391338   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Tyrosine-protein kinase JAK2 (Homo sapiens (Human))	BDBM391338 (Trans 2-(4-(3-Fluoroazetidin- 1-yl)-1-(3-((2-methy...) Show SMILES CN1Cc2cc(Nc3nn(c4cc[nH]c(=O)c34)[C@@]3(CC#N)CC[C@@H](CC3)N3CC(F)C3)ccc2S1(=O)=O |r,wU:17.18,wD:23.28,(1.9,-7.72,;.57,-6.95,;.57,-5.41,;-.89,-4.93,;-1.52,-3.52,;-3.05,-3.36,;-3.45,-1.88,;-2.36,-.79,;-.83,-.95,;-.2,.46,;-1.35,1.49,;-1.35,3.03,;-2.68,3.8,;-4.01,3.03,;-4.01,1.49,;-5.35,.72,;-2.68,.72,;1.28,.86,;.02,-.03,;.16,-1.56,;.29,-3.09,;.2,1.95,;.59,3.43,;2.08,3.83,;3.17,2.74,;2.77,1.26,;2.48,5.32,;3.81,6.09,;3.04,7.42,;3.44,8.91,;1.71,6.65,;-3.96,-4.61,;-3.33,-6.02,;-1.8,-6.18,;-.89,-7.42,;-1.98,-8.51,;-.49,-8.91,)| Show InChI	PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.0900	n/a	n/a	n/a	n/a	n/a	n/a
GSK					Assay Description The ability of compounds to inhibit the activity of JAK1, JAK2, JAK3, and Tyk2 was measured using a recombinant purified GST-tagged catalytic domain ...				Bioorg Med Chem Lett 19: 360-4 (2009) BindingDB Entry DOI: 10.7270/Q2KH0QN8
					More data for this Ligand-Target Pair
Tyrosine-protein kinase JAK1 (Homo sapiens (Human))	BDBM391338 (Trans 2-(4-(3-Fluoroazetidin- 1-yl)-1-(3-((2-methy...) Show SMILES CN1Cc2cc(Nc3nn(c4cc[nH]c(=O)c34)[C@@]3(CC#N)CC[C@@H](CC3)N3CC(F)C3)ccc2S1(=O)=O |r,wU:17.18,wD:23.28,(1.9,-7.72,;.57,-6.95,;.57,-5.41,;-.89,-4.93,;-1.52,-3.52,;-3.05,-3.36,;-3.45,-1.88,;-2.36,-.79,;-.83,-.95,;-.2,.46,;-1.35,1.49,;-1.35,3.03,;-2.68,3.8,;-4.01,3.03,;-4.01,1.49,;-5.35,.72,;-2.68,.72,;1.28,.86,;.02,-.03,;.16,-1.56,;.29,-3.09,;.2,1.95,;.59,3.43,;2.08,3.83,;3.17,2.74,;2.77,1.26,;2.48,5.32,;3.81,6.09,;3.04,7.42,;3.44,8.91,;1.71,6.65,;-3.96,-4.61,;-3.33,-6.02,;-1.8,-6.18,;-.89,-7.42,;-1.98,-8.51,;-.49,-8.91,)| Show InChI	PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.0400	n/a	n/a	n/a	n/a	n/a	n/a
GSK					Assay Description The ability of compounds to inhibit the activity of JAK1, JAK2, JAK3, and Tyk2 was measured using a recombinant purified GST-tagged catalytic domain ...				Bioorg Med Chem Lett 19: 360-4 (2009) BindingDB Entry DOI: 10.7270/Q2KH0QN8
					More data for this Ligand-Target Pair